


dysphoric disease (PMDD), HAIR-AN syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans), ovarian hyperthecosis (HAIR-AN with hyperplasia of luteinized theca cells in ovarian stroma), other manifestations of high intraovarian androgen concentrations (e.g. follicular maturation arrest, atresia, anovulation, dysmenorrhea, dysfunctional uterine bleeding, infertility), androgen-producing tumor (virilizing ovarian or adrenal tumor), menorrhagia and adenomyosis.

- ~~16. A compound according to anyone of claims 1 to 12 or a pharmaceutically acceptable solvate thereof for use in lowering and/or suppressing the LH surge in assisted conception in a patient.~~
16. A compound according to anyone of claims 1 to 12 or a pharmaceutically acceptable solvate thereof for use in treating and/or preventing hot flashes.
- ~~17. A compound according to anyone of claims 1 to 12 or a pharmaceutically acceptable solvate thereof for use in causing male castration and inhibiting the sex drive in men.~~
17. The compound for use according to claim 16, wherein the compound is (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone or a pharmaceutically acceptable solvate thereof.
18. Process of manufacturing a compound according to anyone of claims 1 to 12 or a pharmaceutically acceptable solvate thereof, characterized in that it comprises the following steps:
- a) reacting a compound of Formula (i)



(i)

wherein:

PG represents a suitable protecting group such as for example DMB, PMB, Boc, allyl, diphenyl-phosphoramidate or 2-trimethylsilylethanesulfonyl;

R^{4'} is **R⁴** as defined in claim 1 or a reducible precursor of hydroxyethyl and consequently a further precursor of methoxyethyl;

* - - stands for the (*R*)-enantiomer or for the racemate;